dc.contributor
Institut Català de la Salut
dc.contributor
[Koessler T] Department of Oncology, Geneva University Hospital, Geneva, Switzerland. Swiss Cancer Center Leman (SCCL), University of Geneva, Lausanne, Switzerland. [Alsina M] Hospital Universitario de Navarra (HUN), Medical Oncology Department, Pamplona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Arnold D] Department of Oncology, Haematology and Palliative Care, Asklepios Klinik Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany. [Ben-Aharon I] Division of Oncology, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel. [Collienne M] Department of Oncology, Haematology and Palliative Care, Asklepios Klinik Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany. European Organisation for Research and Treatment of Cancer, Brussels, Belgium. [Lutz MP] Caritasklinikum, Saarbrucken, Germany
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Koessler, Thibaud
dc.contributor.author
Alsina Maqueda, Maria
dc.contributor.author
Arnold, Dirk
dc.contributor.author
Ben-Aharon, Irit
dc.contributor.author
Collienne, M.
dc.contributor.author
Lutz, Manfred
dc.date.accessioned
2025-10-25T05:38:41Z
dc.date.available
2025-10-25T05:38:41Z
dc.date.issued
2022-10-28T12:42:25Z
dc.date.issued
2022-10-28T12:42:25Z
dc.identifier
Koessler T, Alsina M, Arnold D, Ben-Aharon I, Collienne M, Lutz MP, et al. ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective. ESMO Open. 2022 Apr;7(2):100392.
dc.identifier
https://hdl.handle.net/11351/8366
dc.identifier
10.1016/j.esmoop.2022.100392
dc.identifier
000819921700001
dc.identifier.uri
http://hdl.handle.net/11351/8366
dc.description.abstract
Neuroendocrine tumours; Pancreatic cancer; Stomach cancer
dc.description.abstract
Tumores neuroendocrinos; Cáncer de páncreas; Cáncer de estómago
dc.description.abstract
Tumors neuroendocrins; Càncer de pàncrees; Càncer d'estómac
dc.description.abstract
There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future.
dc.description.abstract
This work was supported by a donation from the Swiss Cancer Research Foundation from Switzerland. MC was supported by a grant by EORTC Cancer Research Fund (ECRF) and the Gastrointestinal Tract Cancer Group.
dc.format
application/pdf
dc.relation
ESMO Open;7(2)
dc.relation
https://doi.org/10.1016/j.esmoop.2022.100392
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Aparell digestiu - Càncer - Tractament
dc.subject
Estómac - Càncer - Tractament
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia
dc.title
ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group’s perspective
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
